Navigation Links
Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership
Date:5/13/2010

TIANJIN, China, May 13 /PRNewswire-Asia/ -- A signing ceremony for a strategic partnership agreement between Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) and Genzyme Corporation was held in the Tianjin Economic-Technological Development Area (TEDA) on 10 May.

Officials and executives including Rao Zihe, President of TJAB and President of Nankai University, He Shushan, Director of TEDA Administrative Commission and Standing Committee Member of the CPC Committee of the Binhai New Area, Li Baochun, Deputy Director of the Tianjin Municipal Science and Technology Commission, Huang Yalou, Director of the Binhai New Area Science and Technology Commission, Zhang Yaozhou, Vice president of TJAB, Richard Gregory, Senior VP and Head of Research, Genzyme, Canwen Jiang, Vice President and Head of R&D Asia, Genzyme, and Shan Jizhong, General Manager of Genzyme Beijing Biotechnology Co. Ltd, attended the signing ceremony.

Genzyme is one of the world's ten leading biotechnology companies. The company has grown to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of US$4.5 billion. The company is committed to developing and applying the most advanced technologies in life sciences, with the research and development efforts spanning a range of medical areas including cardiovascular disease.

TJAB, co-founded by the Ministry of Science and Technology, the Ministry of Commerce, the Ministry of Health, the State Food and Drug Administration and the Tianjin Municipal People's Government, officially opened in June 2009. As the core and symbol of the BioMed Zone, the academy received RMB1.1 billion of investment from the Tianjin Binhai New Area which was used to install specialized apparatus and devices. Leveraging its one-stop service system and dedicated public technology platform, TJAB has been committed to accelerating the process from new drug development to industrialization.

The strategic partnership between TJAB and Genzyme in the fields of application and translational research, preclinical and clinical study, diagnostic testing and therapy, as well as doctoral and postdoctoral education training will help quickly and successfully bring the company's innovative drugs to China, promoting innovation and development of the Chinese biopharmaceutical industry.


'/>"/>
SOURCE Tianjin Economic-Technological Development Area (TEDA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye International Announces First Quarter 2010 Results
2. Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites
3. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
4. Yongye International Announces Conference Call to Discuss First Quarter Fiscal Year 2010 Results
5. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
6. Yongye International to Present at Upcoming Investor Conferences
7. Yongye International, Inc. Begins Construction of New Production Facility
8. Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010
9. Dyadic International Strengthens Management Team
10. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
11. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/5/2016)... Australian-US drug discovery and development company, Novogen Limited ... a new Chairman, Mr John O,Connor , and new ... James Garner , has also been formally appointed ... CEO, Mr Iain Ross , will resume his role ... James Garner , has also been formally appointed to the ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ... "Emotion Detection and Recognition Market by Technology ... Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020" report to ... ) has announced the addition of the ...
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
Breaking Biology News(10 mins):